NO20084832L - Pyrimidinderivater som P13K-inhibitorer - Google Patents
Pyrimidinderivater som P13K-inhibitorerInfo
- Publication number
- NO20084832L NO20084832L NO20084832A NO20084832A NO20084832L NO 20084832 L NO20084832 L NO 20084832L NO 20084832 A NO20084832 A NO 20084832A NO 20084832 A NO20084832 A NO 20084832A NO 20084832 L NO20084832 L NO 20084832L
- Authority
- NO
- Norway
- Prior art keywords
- group
- alk
- unsubstituted
- alkyl
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
Abstract
Tienopyrimidiner med formel (Ia) eller (Ib): hvori R1 er en gruppe med formel: R2 er H, halo eller C1-C6 alkyl; R3 er en indolgruppe som er usubstituert eller substituert; R4 og R5 danner, sammen med N-atomet som de er bundet til, en gruppe valgt fra piperazin, piperidin og pyrrolidin, hvis gruppe er usubstituert eller substituert med en eller flere grupper valgt fra C1-C6 alkyl, -S(O)2 R10 , -S(O)2-(alk)q-NR11R12, okso (=O), -alk-OR10 , -(alk)q-Het, en heterosyklylgruppe og -NR13R14; eller en av R4 og R5 er C1-C6 alkyl og den andre er en piperazin-, piperidin- eller pyrrolidingruppe, hvis gruppe er usubstituert eller substituert; R10 er H eller C1-C6 alkyl som er usubstituert; R11 og R12 er hver uavhengig valgt fra H og C1-C6 alkyl som er usubstituert, eller R11 og R12 danner, sammen med N-atomet som de er bundet til, en 5- eller 6-leddet mettet heterosyklisk gruppe; R13 og R14 er hver uavhengig valgt fra C1-C6 alkyl, -S(O)2 R10, alk-OR10, -(alk)q-Ph og -(alk)q-Het; Ph er fenyl; q er 0 eller 1; Het er en tiazol-, imidazol-, pyrrol-, pyridin- eller pyrimidingruppe, hvis gruppe er usubstituert eller substituert; og alk er C1-C6 alkylen; og de farmasøytisk akseptable saltene derav har aktivitet som inhibitorer av PI3K og kan således bli brukt for å behandle sykdommer og forstyrrelser som kommer som et resultat av abnorm cellevekst, -funksjon eller -oppførsel assosiert med PI3 kinase, spesielt p110 delta subtypen, sånn som immunforstyrrelser, kardiovaskulær sykdom, viral infeksjon, inflammasjon, metabolske/endokrine forstyrrelser og neurologiske forstyrrelser. Prosesser for å syntetisere forbindelsene er også beskrevet.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0608264A GB0608264D0 (en) | 2006-04-26 | 2006-04-26 | Pharmaceutical compounds |
GB0608397A GB0608397D0 (en) | 2006-04-27 | 2006-04-27 | Pharmaceutical compounds |
PCT/GB2007/001504 WO2007122410A1 (en) | 2006-04-26 | 2007-04-25 | Pyrimidine derivatives as pi3k inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20084832L true NO20084832L (no) | 2008-11-18 |
Family
ID=38110021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20084832A NO20084832L (no) | 2006-04-26 | 2008-11-18 | Pyrimidinderivater som P13K-inhibitorer |
Country Status (15)
Country | Link |
---|---|
US (2) | US8252792B2 (no) |
EP (1) | EP2032582A1 (no) |
JP (1) | JP5302186B2 (no) |
KR (1) | KR20090021155A (no) |
AU (1) | AU2007242594A1 (no) |
BR (1) | BRPI0710866A2 (no) |
CA (1) | CA2650196A1 (no) |
CR (1) | CR10369A (no) |
EC (1) | ECSP088867A (no) |
IL (1) | IL194755A0 (no) |
MA (1) | MA30360B1 (no) |
MX (1) | MX2008013582A (no) |
NO (1) | NO20084832L (no) |
RU (1) | RU2008141356A (no) |
WO (1) | WO2007122410A1 (no) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007243457B2 (en) | 2006-04-26 | 2012-02-23 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
BRPI0717907A2 (pt) | 2006-12-07 | 2013-11-05 | Genentech Inc | "composto, composição farmacêutica, métodos para tratar um câncer, para inbir ou modular a atividade da lipídeo quinase, processo para a produçãoo de uma composição farmacêutica, uso de um composto e kit" |
JP5284977B2 (ja) | 2006-12-07 | 2013-09-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ホスホイノシチド3−キナーゼ阻害剤化合物及び使用方法 |
CN101679456B (zh) * | 2007-06-12 | 2012-09-05 | 霍夫曼-拉罗奇有限公司 | 噻唑并嘧啶类和它们作为磷脂酰肌醇3-激酶的抑制剂的应用 |
BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
CN101932587A (zh) | 2007-09-24 | 2010-12-29 | 吉宁特有限公司 | 噻唑并嘧啶pi3k抑制剂化合物及使用方法 |
WO2009055730A1 (en) * | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
GB0721095D0 (en) * | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
RU2473549C2 (ru) | 2008-07-31 | 2013-01-27 | Дженентек, Инк. | Пиримидиновые соединения, композиции и способы применения |
US8778927B2 (en) | 2008-10-01 | 2014-07-15 | Novartis Ag | Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
DK2385832T3 (en) | 2009-01-08 | 2015-09-21 | Curis Inc | Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel |
CA2761445A1 (en) | 2009-05-27 | 2010-12-02 | Genentech, Inc. | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
EP2451811A1 (en) | 2009-05-27 | 2012-05-16 | F. Hoffmann-La Roche AG | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
JP5721706B2 (ja) * | 2009-06-17 | 2015-05-20 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インフルエンザウイルス複製の阻害剤 |
AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
MX2012002059A (es) | 2009-08-20 | 2012-04-19 | Karus Therapeutics Ltd | Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa. |
BR112012011188A2 (pt) | 2009-11-12 | 2021-06-29 | F.Hoffmann - La Roche Ag | ''composto,composição farmacêutica e uso de um composto" |
CN102712642B (zh) | 2009-11-12 | 2015-08-12 | 霍夫曼-拉罗奇有限公司 | N-7取代的嘌呤和吡唑并嘧啶化合物、组合物和使用方法 |
BR112013014914B8 (pt) | 2010-12-16 | 2020-08-04 | Hoffmann La Roche | composto, composição farmacêutica e uso de um composto |
UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
KR101761464B1 (ko) | 2012-05-23 | 2017-07-25 | 에프. 호프만-라 로슈 아게 | 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법 |
US20150258127A1 (en) | 2012-10-31 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
US9676765B2 (en) | 2012-11-07 | 2017-06-13 | Karus Therapeutics Limited | Histone deacetylase inhibitors and their use in therapy |
WO2014181137A1 (en) | 2013-05-10 | 2014-11-13 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors |
US9296727B2 (en) | 2013-10-07 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines |
CN105849100B (zh) | 2013-11-13 | 2019-07-16 | 沃泰克斯药物股份有限公司 | 流感病毒复制抑制剂 |
SI3421468T1 (sl) | 2013-11-13 | 2021-03-31 | Vertex Pharmaceuticals Incorporated | Postopki za pripravo inhibitorjev replikacije virusov influence |
GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
DK3230289T3 (da) | 2014-12-11 | 2019-10-28 | Natco Pharma Ltd | 7-(Morpholinyl)-2-(N-piperazinyl)-methylthieno-2, 3-c]pyridinderivativer som anticancer-lægemidler |
WO2016147543A1 (en) | 2015-03-13 | 2016-09-22 | Ricoh Company, Ltd. | Electrochromic compound, electrochromic composition, electrochromic element, and electrochromic dimming element |
EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
JP6857617B2 (ja) | 2015-05-13 | 2021-04-14 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インフルエンザウイルスの複製の阻害剤 |
GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
US10562849B2 (en) * | 2016-05-16 | 2020-02-18 | The Board Of Regents Of The University Of Texas System | Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids |
IL307871A (en) * | 2021-04-21 | 2023-12-01 | Natco Pharma Ltd | PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69943144D1 (de) | 1998-03-31 | 2011-03-03 | Kyowa Hakko Kirin Co Ltd | Stickstoffenthaltende heterocyclische verbindungen |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
EP1277738B1 (en) * | 2000-04-27 | 2011-03-30 | Astellas Pharma Inc. | Condensed heteroaryl derivatives |
WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
AU2007243457B2 (en) | 2006-04-26 | 2012-02-23 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
-
2007
- 2007-04-25 KR KR1020087028890A patent/KR20090021155A/ko not_active Application Discontinuation
- 2007-04-25 EP EP07732542A patent/EP2032582A1/en not_active Withdrawn
- 2007-04-25 WO PCT/GB2007/001504 patent/WO2007122410A1/en active Application Filing
- 2007-04-25 RU RU2008141356/04A patent/RU2008141356A/ru not_active Application Discontinuation
- 2007-04-25 BR BRPI0710866-4A patent/BRPI0710866A2/pt not_active Application Discontinuation
- 2007-04-25 JP JP2009507152A patent/JP5302186B2/ja not_active Expired - Fee Related
- 2007-04-25 US US12/298,507 patent/US8252792B2/en not_active Expired - Fee Related
- 2007-04-25 CA CA002650196A patent/CA2650196A1/en not_active Abandoned
- 2007-04-25 MX MX2008013582A patent/MX2008013582A/es not_active Application Discontinuation
- 2007-04-25 AU AU2007242594A patent/AU2007242594A1/en not_active Abandoned
-
2008
- 2008-10-15 CR CR10369A patent/CR10369A/es not_active Application Discontinuation
- 2008-10-22 IL IL194755A patent/IL194755A0/en unknown
- 2008-10-27 MA MA31338A patent/MA30360B1/fr unknown
- 2008-11-05 EC EC2008008867A patent/ECSP088867A/es unknown
- 2008-11-18 NO NO20084832A patent/NO20084832L/no not_active Application Discontinuation
-
2012
- 2012-07-19 US US13/553,650 patent/US8697693B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
IL194755A0 (en) | 2009-08-03 |
MX2008013582A (es) | 2009-01-19 |
ECSP088867A (es) | 2008-12-30 |
KR20090021155A (ko) | 2009-02-27 |
CR10369A (es) | 2009-01-09 |
JP5302186B2 (ja) | 2013-10-02 |
US8697693B2 (en) | 2014-04-15 |
MA30360B1 (fr) | 2009-04-01 |
RU2008141356A (ru) | 2010-06-10 |
BRPI0710866A2 (pt) | 2012-08-14 |
WO2007122410A1 (en) | 2007-11-01 |
CA2650196A1 (en) | 2007-11-01 |
US8252792B2 (en) | 2012-08-28 |
AU2007242594A1 (en) | 2007-11-01 |
EP2032582A1 (en) | 2009-03-11 |
US20120283257A1 (en) | 2012-11-08 |
JP2009534453A (ja) | 2009-09-24 |
US20100016306A1 (en) | 2010-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20084832L (no) | Pyrimidinderivater som P13K-inhibitorer | |
NO20072115L (no) | Farmasoytiske forbindelser | |
AU2008274670B2 (en) | Pyridazinone derivates | |
NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
KR20210040368A (ko) | 사이클린 의존성 키나제의 억제제 | |
AU2014211856B2 (en) | Substituted 2-aminopyridine protein kinase inhibitor | |
MX2009008465A (es) | Nuevas 2-aminooxazolinas como ligandos de taar1. | |
HRP20140252T1 (hr) | Derivati imidazola kao inhibitori kazeinske kinaze | |
JP2008540626A5 (no) | ||
NO20073926L (no) | Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser | |
NO20063452L (no) | Benzamid-derivater og deres anvendelse som glukokinaseaktiversingsmidler | |
MX2013010140A (es) | Amino-quinolinas como inhibidores de cinasa. | |
CA2729557A1 (en) | Chemical compounds 251 | |
JP2009510086A5 (no) | ||
PE20080772A1 (es) | Nuevos derivados de bipiridina sustituidos y su uso | |
WO2013089212A1 (ja) | 置換トリアジン誘導体およびそれらを含有する医薬組成物 | |
MX2014006210A (es) | Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson. | |
MX2009010884A (es) | 2-morfolin-4-il-pirimidinas como inhibidores de fosfatidilinositol-3-cinasa (pi3k). | |
WO2014145015A2 (en) | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities | |
AR061656A1 (es) | Compuesto de bencilpiperazina, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y procesos para la preparacion de la composicion y del compuesto | |
WO2013066831A1 (en) | Compounds and methods | |
NO20074311L (no) | Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet | |
NO20073283L (no) | Nye pyridotienopyrimidinderivater | |
TR200102789T2 (tr) | Cns bozukluklarının tedavisi için 1-Arensülfonil-2-aril-pirolidin ve piperidin türevleri | |
NO20073271L (no) | Nye pyridotienopyrimidinderivater |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |